Drug Profile
KNI 272
Alternative Names: Kynostatin 272Latest Information Update: 23 Apr 2003
Price :
$50
*
At a glance
- Originator Japan Energy Corporation
- Class Oligopeptides
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections; HIV-1 infections
Most Recent Events
- 02 May 2001 A study has been added to the adverse events, pharmacokinetics and Viral Infections therapeutic trials sections
- 11 Feb 2000 A phase I study has been added to the pharmacokinetics, adverse events and therapeutic trials sections
- 29 Dec 1998 A study has been added to the antimicrobial activities and pharmacokinetics section